Nicole-Claudia Meisner

mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure.

Approximately 3 000 genes are regulated in a time‐, tissue‐, and stimulus‐dependent manner by degradation or stabilization of their mRNAs. The process is mediated by interaction of AU‐rich elements (AREs) in the mRNAs 3′‐untranslated regions with trans‐acting factors. AU‐rich element‐controlled genes of fundamentally different functional relevance depend for their activation on one positive regulator, HuR. Here we present a methodology to exploit this central regulatory process for specific manipulation of AU‐rich element‐controlled gene expression at the mRNA level. With a combination of single‐molecule spectroscopy, computational biology, and molecular and cellular biochemistry, we show that mRNA recognition by HuR is dependent on the presentation of the sequence motif NNUUNNUUU in single‐stranded conformation. The presentation of the HuR binding site in the mRNA secondary structure appears to act analogously to a regulatory on/off switch that specifically controls HuR access to mRNAs in cis. Based on this finding we present a methodology for manipulating ARE mRNA levels by actuating this conformational switch specifically in a target mRNA. Computationally designed oligonucleotides (openers) enhance the NNUUNNUUU accessibility by rearranging the mRNA conformation. Thereby they increase in vitro and endogenous HuR–mRNA complex formation which leads to specific mRNA stabilization (as demonstrated for TNFα and IL‐2, respectively). Induced HuR binding both inside and outside the AU‐rich element promotes functional IL‐2 mRNA stabilization. This opener‐induced mRNA stabilization mimics the endogenous IL‐2 response to CD28 stimulation in human primary T‐cells. We therefore propose that controlled modulation of the AU‐rich element conformation by mRNA openers or closers allows message stabilization or destabilization in cis to be specifically triggered. The described methodology might provide a means for studying distinct pathways in a complex cellular network at the node of mRNA stability control. It allows ARE gene expression to be potentially silenced or boosted. This will be of particular value for drug‐target validation, allowing the diseased phenotype to ameliorate or deteriorate. Finally, the mRNA openers provide a rational starting point for target‐specific mRNA stability assays to screen for low‐molecular‐weight compounds acting as inhibitors or activators of an mRNA structure rearrangement.

Single bead labeling method for combining confocal fluorescence on-bead screening and solution validation of tagged one-bead one-compound libraries.

Screening of one-bead one-compound libraries by incubating beads with fluorescently labeled target protein requires isolation and structure elucidation of a large number of primary hit beads. However, the potency of the identified ligands is only revealed after time consuming and expensive larger scale resynthesis and testing in solution. Often, many of the resynthesized compounds turn out to be weak target binders in solution due to large differences between surface and solution binding affinities. For an industry style high-throughput screening (HTS) process a high false positive rate is detrimental. We have therefore combined single bead and single molecule/single cell techniques into an integrated HTS process in which the picomole amount of substance contained on one isolated hit bead is sufficient for quality control, structure determination, and precise affinity determination to the target protein in solution.

Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries

In eukaryotic cells, proteins and RNAs are transported between the nucleus and the cytoplasm by nuclear import and export receptors. Over the past decade, small molecules that inhibit the nuclear export receptor CRM1 have been identified, most notably leptomycin B. However, up to now no small molecule inhibitors of nuclear import have been described. Here we have used our automated confocal nanoscanning and bead picking method (CONA) for on-bead screening of a one-bead one-compound library to identify the first such import inhibitor, karyostatin 1A. Karyostatin 1A binds importin β with high nanomolar affinity and specifically inhibits importin α/β mediated nuclear import at low micromolar concentrations in vitro and in living cells, without perturbing transportin mediated nuclear import or CRM1 mediated nuclear export. Surface plasmon resonance binding experiments suggest that karyostatin 1A acts by disrupting the interaction between importin β and the GTPase Ran. As a selective inhibitor of the importin α/β import pathway, karyostatin 1A will provide a valuable tool for future studies of nucleocytoplasmic trafficking.

A Highly Potent and Cellularly Active β-Peptidic Inhibitor of the p53/hDM2 Interaction

New and improved: The incorporation of a 6‐chlorotryptophan (6‐Cl‐Trp) into a β‐peptide (M)‐314 helix leads to a high‐affinity hDM2 inhibitor, as demonstrated by fluorescence fluctuation analysis at single molecule resolution. When conjugated to penetratin, the newly derived hDM2 binder specifically inhibits tumour cell growth in vitro.

Confocal fluorescence detection expanded to UV excitation: the first continuous fluorimetric assay of human steroid sulfatase in nanoliter volume.

Steroid sulfatase is an enzyme that currently enjoys considerable interest as a potential drug target in the treatment of estrogen- and androgen-dependent diseases, in particular breast cancer. We have purified human steroid sulfatase to apparent homogeneity from recombinant Chinese hamster ovary cells, and we established an assay with a new fluorogenic substrate, 3,4-benzocoumarin-7-O-sulfate (1). Substrate 1 features a K(m) value of 22.5 microM, which is close to the value for the natural substrate dehydroepiandrosterone sulfate (26 microM) and much lower than the K(m) values of other synthetic substrates (276-736 microM). Importantly, the cleavage of substrate 1 can be monitored continuously during the enzymatic cleavage, since a change in fluorescence intensity is detectable at the pH where the enzyme is active; in contrast, all other synthetic substrates described so far require alkalization to reveal a measurable absorbance or fluorescence signal. The adaptation of the assay to the 96-well format allows continuous monitoring of multiple wells in a microplate fluorescence reader. Applications of the assay for the determination of IC(50) and K(i) values of novel steroid sulfatase inhibitors are presented. Most importantly the assay was transferred to the nanoscale format (1-microl assay volume) in 2080-well plates with confocal fluorescence detection. This miniaturization will permit screening with a minimum throughput of 20000 compounds per day. The system presented demonstrates that the confocal detection platform used for nanoscreening can be successfully adapted to assays for which conventional ultraviolet dyes like coumarins are necessary. This strongly broadens the application range of confocal readers in drug screening.

Abstract 5416: The low-molecular-weight compound MS-444 selectively targets cancer cells via inhibition of the mRNA stability factor HuR

Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Colorectal cancer (CRC) is the third most common cancer among American adults and a leading cause of cancer-related mortality. The initiation and progression of colorectal tumorigenesis is characterized by genetic alterations that promote aberrant expression of oncogenic and tumor-promoting factors. In normal cells, the mRNAs of these inflammation- and cancer-associated genes are targeted for rapid decay through AU-rich elements (ARE) present in the mRNA 3’UTR. However, loss of ARE-mediated mRNA decay is a characteristic feature contributing to pathogenic gene overexpression in colorectal cancer. Our prior work identified enhanced expression of the RNA-binding protein HuR to occur during colon tumorigenesis and HuR overexpression is correlated with poor clinical prognosis. In this capacity, HuR acts as a mRNA stability factor by promoting ARE-containing mRNA stabilization. Therefore, HuR has emerged as a novel pharmacological target with potential selectivity for cancer cells. This was examined by treating HuR-overexpressing CRC cell lines HCT116, SW480, RKO, and HT-29 with the small molecule inhibitor of HuR MS-444. Growth inhibition was observed in all CRC lines with IC50 values of 7-12 µM and cancer cell selectivity was observed with 4- to 5-fold increased MS-444 IC50 in non-transformed intestinal and colonic epithelial cells. HuR is predominantly nuclear in non-transformed cells, whereas in CRC cells aberrant cytoplasmic HuR trafficking is observed indicating that cytoplasmic localization is a necessary component for HuR-mediated ARE-mRNA stabilization and cancer cell survival. In HCT116 cells treated with MS-444, complete inhibition of cytoplasmic HuR was observed along with induction of apoptosis. Similarly, long-term siRNA-mediated knockdown of HuR in HCT116 cells resulted in cellular apoptosis, and cells with attenuated levels of HuR exhibited a 5-fold higher sensitivity to MS-444 treatment. Expression profiling revealed increased expression of many pro-apoptotic proteins to be present in colon cancer cells resulting from MS-444 treatment. The expression of Fas ligand, a TNF superfamily member, is significantly increased, accompanied by elevated expression of caspase 8 and cell death effectors such as Bax and Bid. These results indicate that MS-444 treatment triggers a Fas-dependent signaling cascade mediated through cellular caspases, thereby resulting in cell death. Taken together, these findings indicate that small molecule-based inhibition of HuR results in selective cancer cell death while also indicating that overexpression of HuR is a necessary component for colorectal tumor cell survival. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5416. doi:10.1158/1538-7445.AM2011-5416